Optimal timing of blood samplings to detect GH inhibition during oral glucose tolerance test

Background In patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose tolerance test (OGTT) is advised as confirmatory test. The procedure of this test generally involves GH measurement every 30 min (30’) from ba...

Full description

Saved in:
Bibliographic Details
Published inJournal of endocrinological investigation Vol. 45; no. 5; pp. 981 - 987
Main Authors Bioletto, F., Prencipe, N., Berton, A. M., Bona, C., Varaldo, E., Gasco, V., Ghigo, E., Grottoli, S.
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.05.2022
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN1720-8386
0391-4097
1720-8386
DOI10.1007/s40618-021-01731-0

Cover

Abstract Background In patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose tolerance test (OGTT) is advised as confirmatory test. The procedure of this test generally involves GH measurement every 30 min (30’) from baseline to +120’ or +180’. However, the optimal timing of samplings for the distinction between patients with or without active acromegaly is still a matter of debate. Methods Sixty-seven healthy subjects and 46 acromegalic patients who achieved documented and persistent long-term cure were enrolled. A greedy algorithm was used to identify the minimal subset of time-points that sufficed to correctly detect GH suppression. Results The sampling at 90’ was the one in which a GH level < 1 μg/L was most frequently achieved (i.e., in 91.3% of cured acromegalic patients and in 91.0% of healthy subjects). Considering the whole cohort, the best combination of 2 time-points was +90’ and +150’ and achieved 95.6% accuracy; the best combination of 3 time-points was +60’, +90’ and +150’ and achieved 99.1% accuracy. The minimal subset of GH determinations that demonstrated perfect accuracy (100%) needed the inclusion of 4 time-points, namely +60’, +90’, +120’ and +150’. Conclusion A subset of 4 time-points (60’ – 90’ – 120’ – 150’) was identified as the most relevant to detect GH suppression at OGTT, with a perfect classification of 100% of subjects. This supports the possibility to restrict the blood samplings to these time-points when assessing disease cure, with possible advantages in terms of saving time and lowering costs.
AbstractList In patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose tolerance test (OGTT) is advised as confirmatory test. The procedure of this test generally involves GH measurement every 30 min (30') from baseline to +120' or +180'. However, the optimal timing of samplings for the distinction between patients with or without active acromegaly is still a matter of debate. Sixty-seven healthy subjects and 46 acromegalic patients who achieved documented and persistent long-term cure were enrolled. A greedy algorithm was used to identify the minimal subset of time-points that sufficed to correctly detect GH suppression. The sampling at 90' was the one in which a GH level < 1 μg/L was most frequently achieved (i.e., in 91.3% of cured acromegalic patients and in 91.0% of healthy subjects). Considering the whole cohort, the best combination of 2 time-points was +90' and +150' and achieved 95.6% accuracy; the best combination of 3 time-points was +60', +90' and +150' and achieved 99.1% accuracy. The minimal subset of GH determinations that demonstrated perfect accuracy (100%) needed the inclusion of 4 time-points, namely +60', +90', +120' and +150'. A subset of 4 time-points (60' - 90' - 120' - 150') was identified as the most relevant to detect GH suppression at OGTT, with a perfect classification of 100% of subjects. This supports the possibility to restrict the blood samplings to these time-points when assessing disease cure, with possible advantages in terms of saving time and lowering costs.
In patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose tolerance test (OGTT) is advised as confirmatory test. The procedure of this test generally involves GH measurement every 30 min (30') from baseline to +120' or +180'. However, the optimal timing of samplings for the distinction between patients with or without active acromegaly is still a matter of debate.BACKGROUNDIn patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose tolerance test (OGTT) is advised as confirmatory test. The procedure of this test generally involves GH measurement every 30 min (30') from baseline to +120' or +180'. However, the optimal timing of samplings for the distinction between patients with or without active acromegaly is still a matter of debate.Sixty-seven healthy subjects and 46 acromegalic patients who achieved documented and persistent long-term cure were enrolled. A greedy algorithm was used to identify the minimal subset of time-points that sufficed to correctly detect GH suppression.METHODSSixty-seven healthy subjects and 46 acromegalic patients who achieved documented and persistent long-term cure were enrolled. A greedy algorithm was used to identify the minimal subset of time-points that sufficed to correctly detect GH suppression.The sampling at 90' was the one in which a GH level < 1 μg/L was most frequently achieved (i.e., in 91.3% of cured acromegalic patients and in 91.0% of healthy subjects). Considering the whole cohort, the best combination of 2 time-points was +90' and +150' and achieved 95.6% accuracy; the best combination of 3 time-points was +60', +90' and +150' and achieved 99.1% accuracy. The minimal subset of GH determinations that demonstrated perfect accuracy (100%) needed the inclusion of 4 time-points, namely +60', +90', +120' and +150'.RESULTSThe sampling at 90' was the one in which a GH level < 1 μg/L was most frequently achieved (i.e., in 91.3% of cured acromegalic patients and in 91.0% of healthy subjects). Considering the whole cohort, the best combination of 2 time-points was +90' and +150' and achieved 95.6% accuracy; the best combination of 3 time-points was +60', +90' and +150' and achieved 99.1% accuracy. The minimal subset of GH determinations that demonstrated perfect accuracy (100%) needed the inclusion of 4 time-points, namely +60', +90', +120' and +150'.A subset of 4 time-points (60' - 90' - 120' - 150') was identified as the most relevant to detect GH suppression at OGTT, with a perfect classification of 100% of subjects. This supports the possibility to restrict the blood samplings to these time-points when assessing disease cure, with possible advantages in terms of saving time and lowering costs.CONCLUSIONA subset of 4 time-points (60' - 90' - 120' - 150') was identified as the most relevant to detect GH suppression at OGTT, with a perfect classification of 100% of subjects. This supports the possibility to restrict the blood samplings to these time-points when assessing disease cure, with possible advantages in terms of saving time and lowering costs.
BackgroundIn patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose tolerance test (OGTT) is advised as confirmatory test. The procedure of this test generally involves GH measurement every 30 min (30’) from baseline to +120’ or +180’. However, the optimal timing of samplings for the distinction between patients with or without active acromegaly is still a matter of debate.MethodsSixty-seven healthy subjects and 46 acromegalic patients who achieved documented and persistent long-term cure were enrolled. A greedy algorithm was used to identify the minimal subset of time-points that sufficed to correctly detect GH suppression.ResultsThe sampling at 90’ was the one in which a GH level < 1 μg/L was most frequently achieved (i.e., in 91.3% of cured acromegalic patients and in 91.0% of healthy subjects). Considering the whole cohort, the best combination of 2 time-points was +90’ and +150’ and achieved 95.6% accuracy; the best combination of 3 time-points was +60’, +90’ and +150’ and achieved 99.1% accuracy. The minimal subset of GH determinations that demonstrated perfect accuracy (100%) needed the inclusion of 4 time-points, namely +60’, +90’, +120’ and +150’.ConclusionA subset of 4 time-points (60’ – 90’ – 120’ – 150’) was identified as the most relevant to detect GH suppression at OGTT, with a perfect classification of 100% of subjects. This supports the possibility to restrict the blood samplings to these time-points when assessing disease cure, with possible advantages in terms of saving time and lowering costs.
Background In patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose tolerance test (OGTT) is advised as confirmatory test. The procedure of this test generally involves GH measurement every 30 min (30’) from baseline to +120’ or +180’. However, the optimal timing of samplings for the distinction between patients with or without active acromegaly is still a matter of debate. Methods Sixty-seven healthy subjects and 46 acromegalic patients who achieved documented and persistent long-term cure were enrolled. A greedy algorithm was used to identify the minimal subset of time-points that sufficed to correctly detect GH suppression. Results The sampling at 90’ was the one in which a GH level < 1 μg/L was most frequently achieved (i.e., in 91.3% of cured acromegalic patients and in 91.0% of healthy subjects). Considering the whole cohort, the best combination of 2 time-points was +90’ and +150’ and achieved 95.6% accuracy; the best combination of 3 time-points was +60’, +90’ and +150’ and achieved 99.1% accuracy. The minimal subset of GH determinations that demonstrated perfect accuracy (100%) needed the inclusion of 4 time-points, namely +60’, +90’, +120’ and +150’. Conclusion A subset of 4 time-points (60’ – 90’ – 120’ – 150’) was identified as the most relevant to detect GH suppression at OGTT, with a perfect classification of 100% of subjects. This supports the possibility to restrict the blood samplings to these time-points when assessing disease cure, with possible advantages in terms of saving time and lowering costs.
Author Varaldo, E.
Bioletto, F.
Gasco, V.
Ghigo, E.
Prencipe, N.
Berton, A. M.
Grottoli, S.
Bona, C.
Author_xml – sequence: 1
  givenname: F.
  orcidid: 0000-0001-7550-7023
  surname: Bioletto
  fullname: Bioletto, F.
  email: fabio.bioletto@unito.it
  organization: Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin
– sequence: 2
  givenname: N.
  surname: Prencipe
  fullname: Prencipe, N.
  organization: Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin
– sequence: 3
  givenname: A. M.
  surname: Berton
  fullname: Berton, A. M.
  organization: Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin
– sequence: 4
  givenname: C.
  surname: Bona
  fullname: Bona, C.
  organization: Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin
– sequence: 5
  givenname: E.
  surname: Varaldo
  fullname: Varaldo, E.
  organization: Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin
– sequence: 6
  givenname: V.
  surname: Gasco
  fullname: Gasco, V.
  organization: Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin
– sequence: 7
  givenname: E.
  surname: Ghigo
  fullname: Ghigo, E.
  organization: Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin
– sequence: 8
  givenname: S.
  surname: Grottoli
  fullname: Grottoli, S.
  organization: Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35098493$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1PHSEUhomx8fsPuDAk3XQzFoYZYJbGtGpi4qbdmRAGzlUMdxiBWfTf91yvrcaFGzghzwOH9xyS3SlNQMgpZ-ecMfW9dExy3bCWN4wrgesOOeCqZY0WWu6-q_fJYSlPjAkltNoj-6Jng-4GcUDu7-Ya1jZSXMP0QNOKjjElT4tdzxFPCq2JeqjgKr26pmF6DGOoIU3UL_nFyGg_xMWlAshGyHZyWEGpx-TLysYCJ6_7Efn988evy-vm9u7q5vLitnFC9bXxctRt763VTo6jGpUHcAqweyFW3Om-H1wHgsth9MoBeMalFNJrBRqlQRyRb9t755yeF3zYrENxEKOdIC3FtLLtWvz9sEG_fkCf0pIn7A6pbmC87zuF1NkrtYxr8GbOmFH-Y_7lhkC7BVxOpWRY_Uc4M5vhmO1wDA7HvAzHMJT0B8mFajdZ1mxD_FwVW7XMm9Ahv7X9ifUXFpmjHw
CitedBy_id crossref_primary_10_1007_s40618_024_02396_1
Cites_doi 10.1530/EJE-08-0284
10.1210/jc.2009-2670
10.1007/BF01584082
10.1530/EJE-09-0222
10.1023/B:PITU.0000023424.72021.e2
10.20945/2359-3997000000192
10.1007/s11102-007-0030-1
10.1007/978-1-62703-616-0_7
10.1046/j.1365-2265.1997.1430983.x
10.1373/clinchem.2010.150631
10.1038/s41574-018-0058-5
10.1016/j.tem.2014.10.005
10.1053/meta.2003.50036
10.1530/EJE-11-0657
10.1210/jc.2014-2700
10.1111/j.1365-2265.2004.02064.x
10.1210/er.2002-0022
10.1007/s40618-018-0928-7
10.1210/jc.2007-1191
10.1227/NEU.0b013e31823f5c16
10.1053/meta.2002.32017
10.1517/17530059.2013.820181
10.1210/jc.2012-2477
10.1016/j.matpr.2021.01.691
10.1007/BF02604639
10.1007/s11102-017-0797-7
10.3748/wjg.14.3484
10.1016/S0889-8529(18)30204-4
10.1007/BF03345139
10.1530/EJE-14-0304
ContentType Journal Article
Copyright Italian Society of Endocrinology (SIE) 2021
2021. Italian Society of Endocrinology (SIE).
Italian Society of Endocrinology (SIE) 2021.
Copyright_xml – notice: Italian Society of Endocrinology (SIE) 2021
– notice: 2021. Italian Society of Endocrinology (SIE).
– notice: Italian Society of Endocrinology (SIE) 2021.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
NAPCQ
7X8
DOI 10.1007/s40618-021-01731-0
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
ProQuest Health & Medical Complete (Alumni)

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1720-8386
EndPage 987
ExternalDocumentID 35098493
10_1007_s40618_021_01731_0
Genre Journal Article
GroupedDBID ---
-EM
.GJ
0R~
203
4.4
406
53G
5GY
5RE
8RF
8YF
96X
AACDK
AAEWM
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAZMS
ABAKF
ABDZT
ABECU
ABFTV
ABHLI
ABIPD
ABJNI
ABJOX
ABKCH
ABMQK
ABPLI
ABQBU
ABTEG
ABTKH
ABTMW
ABXPI
ACAOD
ACDTI
ACGFS
ACHSB
ACKNC
ACMLO
ACOKC
ACPIV
ACPRK
ACUDM
ACZOJ
ADHHG
ADINQ
ADJJI
ADKNI
ADKPE
ADURQ
ADYFF
ADZKW
AEBTG
AEFQL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEODN
AEOHA
AEPYU
AESKC
AETCA
AEVLU
AEXYK
AFBBN
AFQWF
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHSBF
AI.
AIAKS
AIGIU
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKLTO
AKMHD
ALFXC
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMXSW
AMYLF
AMYQR
ANMIH
ASPBG
AUKKA
AVWKF
AXYYD
AZFZN
BGNMA
CSCUP
DNIVK
DPUIP
EBLON
EBS
EIOEI
EJD
ESBYG
F5P
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FYJPI
GGCAI
GGRSB
GJIRD
GQ7
GRRUI
HG6
HRMNR
I0C
IKXTQ
IMOTQ
ITM
IWAJR
J-C
JBSCW
JZLTJ
KOV
LLZTM
M4Y
NPVJJ
NQJWS
NU0
O93
O9G
O9J
P2P
PT4
RHV
RLLFE
ROL
RSV
SCLPG
SDE
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
TSG
U9L
UG4
UOJIU
UTJUX
UZXMN
VFIZW
VH1
W48
Z7U
Z83
Z87
ZGI
ZMTXR
ZOVNA
ZXP
AAYXX
ABBRH
ABDBE
ABFSG
ABRTQ
ACSTC
AEZWR
AFDZB
AFHIU
AFOHR
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c375t-d6b825daa8c6bb7b7deec7e17233f1c8559c4e3169bd7ceed016636d87e8aa893
IEDL.DBID AGYKE
ISSN 1720-8386
0391-4097
IngestDate Fri Sep 05 09:17:15 EDT 2025
Tue Oct 07 06:45:51 EDT 2025
Mon Jul 21 06:04:21 EDT 2025
Wed Oct 01 02:53:11 EDT 2025
Thu Apr 24 22:57:01 EDT 2025
Fri Feb 21 02:46:43 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Acromegaly
Oral glucose tolerance test
Growth hormone suppression
Growth hormone
Acromegaly diagnosis
Language English
License 2021. Italian Society of Endocrinology (SIE).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c375t-d6b825daa8c6bb7b7deec7e17233f1c8559c4e3169bd7ceed016636d87e8aa893
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-7550-7023
PMID 35098493
PQID 2649015547
PQPubID 2043718
PageCount 7
ParticipantIDs proquest_miscellaneous_2624200399
proquest_journals_2649015547
pubmed_primary_35098493
crossref_primary_10_1007_s40618_021_01731_0
crossref_citationtrail_10_1007_s40618_021_01731_0
springer_journals_10_1007_s40618_021_01731_0
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-05-01
PublicationDateYYYYMMDD 2022-05-01
PublicationDate_xml – month: 05
  year: 2022
  text: 2022-05-01
  day: 01
PublicationDecade 2020
PublicationPlace Cham
PublicationPlace_xml – name: Cham
– name: Italy
– name: Heidelberg
PublicationSubtitle Official Journal of Italian Society of Endocrinology (SIE)
PublicationTitle Journal of endocrinological investigation
PublicationTitleAbbrev J Endocrinol Invest
PublicationTitleAlternate J Endocrinol Invest
PublicationYear 2022
Publisher Springer International Publishing
Springer Nature B.V
Publisher_xml – name: Springer International Publishing
– name: Springer Nature B.V
References Freda, Reyes, Nuruzzaman, Sundeen, Bruce (CR13) 2003; 6
Schilbach, Bidlingmaier (CR31) 2019; 63
Bidlingmaier (CR29) 2008
Guha (CR30) 2013; 1065
Colao, Ferone, Marzullo, Lombardi (CR9) 2004; 25
Giustina, Chanson, Bronstein, Klibanski, Lamberts, Casanueva (CR16) 2010
Caputo, Ucciero, Mele, De Marchi, Magnani, Cena (CR3) 2019; 42
Rokkas, Pistiolas, Sechopoulos, Margantinis, Koukoulis (CR7) 2008; 14
Minuto, Resmini, Boschetti, Arvigo, Sormani, Giusti (CR19) 2004; 61
Freda, Post, Powell, Wardlaw (CR12) 1998; 83
Grottoli, Razzore, Gaia, Gasperi, Giusti, Colao (CR17) 2003
Ku, Hong, Kim, Kim, Lee (CR25) 2014; 171
Ronchi, Giavoli, Ferrante, Verrua, Bergamaschi, Ferrari (CR26) 2009; 161
De Marinis, Mancini, Bianchi, Gentilella, Valle, Giampietro (CR18) 2002; 51
Kim, Oh, Lee, Kim (CR14) 2012; 70
Edmonds (CR20) 1971; 1
Bidlingmaier, Strasburger (CR28) 2007; 10
Katznelson, Laws, Melmed, Molitch, Murad, Utz (CR1) 2014; 99
Molitch (CR5) 1992; 21
Rajesh Khanna, Shirisha, Kauda (CR22) 2021
Kannan, Kennedy (CR10) 2013; 7
Yamada, Fukuhara, Nishioka, Takeshita, Suzuki, Miyakawa (CR23) 2011; 165
Dekkers, Biermasz, Pereira, Romijn, Vandenbroucke (CR8) 2008; 93
Vierhapper, Heinze, Gessl, Exner, Bieglmayr (CR15) 2003; 52
Pivonello, Auriemma, Grasso, Pivonello, Simeoli, Patalano (CR6) 2017; 20
Stoffel-Wagner, Springer, Bidlingmaier, Klingmüller (CR11) 1997; 46
Melmed, Bronstein, Chanson, Klibanski, Casanueva, Wass (CR2) 2018; 14
Mazziotti, Marzullo, Doga, Aimaretti, Giustina (CR24) 2015; 26
Bouchet (CR21) 1987; 38
Drange, Fram, Herman-Bonert, Melmed (CR4) 2000; 85
Giavoli, Profka, Verrua, Ronchi, Ferrante, Bergamaschi (CR27) 2012; 97
Clemmons (CR32) 2011; 57
S Melmed (1731_CR2) 2018; 14
M Caputo (1731_CR3) 2019; 42
S Grottoli (1731_CR17) 2003
A Giustina (1731_CR16) 2010
G Mazziotti (1731_CR24) 2015; 26
MR Drange (1731_CR4) 2000; 85
A Colao (1731_CR9) 2004; 25
F Minuto (1731_CR19) 2004; 61
H Vierhapper (1731_CR15) 2003; 52
CR Ku (1731_CR25) 2014; 171
DR Clemmons (1731_CR32) 2011; 57
C Giavoli (1731_CR27) 2012; 97
M Bidlingmaier (1731_CR29) 2008
K Rajesh Khanna (1731_CR22) 2021
L De Marinis (1731_CR18) 2002; 51
L Katznelson (1731_CR1) 2014; 99
B Stoffel-Wagner (1731_CR11) 1997; 46
M Bidlingmaier (1731_CR28) 2007; 10
R Pivonello (1731_CR6) 2017; 20
CL Ronchi (1731_CR26) 2009; 161
K Schilbach (1731_CR31) 2019; 63
S Yamada (1731_CR23) 2011; 165
M Molitch (1731_CR5) 1992; 21
S Kannan (1731_CR10) 2013; 7
PU Freda (1731_CR12) 1998; 83
EH Kim (1731_CR14) 2012; 70
J Edmonds (1731_CR20) 1971; 1
PU Freda (1731_CR13) 2003; 6
N Guha (1731_CR30) 2013; 1065
OM Dekkers (1731_CR8) 2008; 93
T Rokkas (1731_CR7) 2008; 14
A Bouchet (1731_CR21) 1987; 38
References_xml – year: 2008
  ident: CR29
  article-title: Problems with GH assays and strategies toward standardization
  publication-title: Eur J Endocrinol
  doi: 10.1530/EJE-08-0284
– year: 2010
  ident: CR16
  article-title: A consensus on criteria for cure of acromegaly
  publication-title: J Clin Endocrinol Metabol Endocrine Soc
  doi: 10.1210/jc.2009-2670
– volume: 1
  start-page: 127
  issue: 1
  year: 1971
  end-page: 136
  ident: CR20
  article-title: Matroids and the greedy algorithm
  publication-title: Mathem Programm.
  doi: 10.1007/BF01584082
– volume: 161
  start-page: 37
  issue: 1
  year: 2009
  end-page: 42
  ident: CR26
  article-title: Prevalence of GH deficiency in cured acromegalic patients: Impact of different previous treatments
  publication-title: Eur J Endocrinol
  doi: 10.1530/EJE-09-0222
– volume: 6
  start-page: 175
  issue: 4
  year: 2003
  end-page: 180
  ident: CR13
  article-title: Basal and glucose-suppressed GH levels less than 1 μg/L in newly diagnosed acromegaly
  publication-title: Pituitary
  doi: 10.1023/B:PITU.0000023424.72021.e2
– volume: 63
  start-page: 618
  issue: 6
  year: 2019
  end-page: 629
  ident: CR31
  article-title: Laboratory investigations in the diagnosis and follow-up of GH-related disorders
  publication-title: Arch Endocrinol Metab
  doi: 10.20945/2359-3997000000192
– volume: 10
  start-page: 115
  issue: 2
  year: 2007
  end-page: 119
  ident: CR28
  article-title: Growth hormone assays: Current methodologies and their limitations
  publication-title: Pituitary
  doi: 10.1007/s11102-007-0030-1
– volume: 83
  start-page: 3808
  issue: 11
  year: 1998
  end-page: 3816
  ident: CR12
  article-title: Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly 1
  publication-title: J Clin Endocrinol Metab
– volume: 1065
  start-page: 117
  year: 2013
  end-page: 128
  ident: CR30
  article-title: Assays for GH, IGF-I, and IGF binding protein-3
  publication-title: Methods Mol Biol
  doi: 10.1007/978-1-62703-616-0_7
– volume: 46
  start-page: 531
  issue: 5
  year: 1997
  end-page: 537
  ident: CR11
  article-title: A comparison of different methods for diagnosing acromegaly
  publication-title: Clin Endocrinol (Oxf)
  doi: 10.1046/j.1365-2265.1997.1430983.x
– volume: 57
  start-page: 555
  issue: 4
  year: 2011
  end-page: 559
  ident: CR32
  article-title: Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2010.150631
– volume: 14
  start-page: 552
  issue: 9
  year: 2018
  end-page: 561
  ident: CR2
  article-title: A consensus statement on acromegaly therapeutic outcomes
  publication-title: Nat Rev Endocrinol
  doi: 10.1038/s41574-018-0058-5
– volume: 26
  start-page: 11
  issue: 1
  year: 2015
  end-page: 21
  ident: CR24
  article-title: Growth hormone deficiency in treated acromegaly
  publication-title: Trends Endocrinol Metab
  doi: 10.1016/j.tem.2014.10.005
– volume: 52
  start-page: 181
  issue: 2
  year: 2003
  end-page: 185
  ident: CR15
  article-title: Use of the oral glucose tolerance test to define remission in acromegaly
  publication-title: Metabolism
  doi: 10.1053/meta.2003.50036
– volume: 165
  start-page: 873
  issue: 6
  year: 2011
  end-page: 879
  ident: CR23
  article-title: GH deficiency in patients after cure of acromegaly by surgery alone
  publication-title: Eur J Endocrinol
  doi: 10.1530/EJE-11-0657
– volume: 99
  start-page: 3933
  issue: 11
  year: 2014
  end-page: 3951
  ident: CR1
  article-title: Acromegaly: An endocrine society clinical practice guideline
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2014-2700
– volume: 61
  start-page: 138
  issue: 1
  year: 2004
  end-page: 144
  ident: CR19
  article-title: Assessment of disease activity in acromegaly by means of a single blood sample: Comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system
  publication-title: Clin Endocrinol (Oxf)
  doi: 10.1111/j.1365-2265.2004.02064.x
– volume: 25
  start-page: 102
  issue: 1
  year: 2004
  end-page: 152
  ident: CR9
  article-title: Systemic complications of acromegaly: epidemiology, pathogenesis, and management
  publication-title: Endocr Rev
  doi: 10.1210/er.2002-0022
– volume: 42
  start-page: 397
  issue: 4
  year: 2019
  end-page: 402
  ident: CR3
  article-title: Use of administrative health databases to estimate incidence and prevalence of acromegaly in Piedmont Region, Italy
  publication-title: J Endocrinol Invest
  doi: 10.1007/s40618-018-0928-7
– volume: 93
  start-page: 61
  issue: 1
  year: 2008
  end-page: 67
  ident: CR8
  article-title: Mortality in acromegaly: a metaanalysis
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2007-1191
– volume: 70
  start-page: 1106
  issue: 5
  year: 2012
  end-page: 1112
  ident: CR14
  article-title: Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly
  publication-title: Neurosurgery
  doi: 10.1227/NEU.0b013e31823f5c16
– volume: 51
  start-page: 616
  issue: 5
  year: 2002
  end-page: 621
  ident: CR18
  article-title: Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: A retrospective evaluation of 50 patients
  publication-title: Metabolism
  doi: 10.1053/meta.2002.32017
– volume: 7
  start-page: 443
  issue: 5
  year: 2013
  end-page: 453
  ident: CR10
  article-title: Diagnosis of acromegaly: State of the art
  publication-title: Expert Opin Med Diagn
  doi: 10.1517/17530059.2013.820181
– volume: 85
  start-page: 168
  issue: 1
  year: 2000
  end-page: 174
  ident: CR4
  article-title: Pituitary tumor registry: a novel clinical resource 1
  publication-title: J Clin Endocrinol Metab
– volume: 97
  start-page: 3983
  issue: 11
  year: 2012
  end-page: 3988
  ident: CR27
  article-title: GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2012-2477
– year: 2021
  ident: CR22
  article-title: A review of approaches and associated dimensions with greedy method for research implementations
  publication-title: Mater Today Proc
  doi: 10.1016/j.matpr.2021.01.691
– volume: 38
  start-page: 147
  issue: 2
  year: 1987
  end-page: 159
  ident: CR21
  article-title: Greedy algorithm and symmetric matroids
  publication-title: Mathem Programm
  doi: 10.1007/BF02604639
– volume: 20
  start-page: 46
  issue: 1
  year: 2017
  end-page: 62
  ident: CR6
  article-title: Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities
  publication-title: Pituitary
  doi: 10.1007/s11102-017-0797-7
– volume: 14
  start-page: 3484
  issue: 22
  year: 2008
  end-page: 3489
  ident: CR7
  article-title: Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.14.3484
– volume: 21
  start-page: 597
  issue: 3
  year: 1992
  end-page: 614
  ident: CR5
  article-title: Clinical manifestations of acromegaly
  publication-title: Endocrinol Metab Clin North Am
  doi: 10.1016/S0889-8529(18)30204-4
– year: 2003
  ident: CR17
  article-title: Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly
  publication-title: J Endocrinol Invest
  doi: 10.1007/BF03345139
– volume: 171
  start-page: 379
  issue: 3
  year: 2014
  end-page: 387
  ident: CR25
  article-title: Clinical predictors of GH deficiency in surgically cured acromegalic patients
  publication-title: Eur J Endocrinol
  doi: 10.1530/EJE-14-0304
– volume: 46
  start-page: 531
  issue: 5
  year: 1997
  ident: 1731_CR11
  publication-title: Clin Endocrinol (Oxf)
  doi: 10.1046/j.1365-2265.1997.1430983.x
– volume: 14
  start-page: 552
  issue: 9
  year: 2018
  ident: 1731_CR2
  publication-title: Nat Rev Endocrinol
  doi: 10.1038/s41574-018-0058-5
– volume: 171
  start-page: 379
  issue: 3
  year: 2014
  ident: 1731_CR25
  publication-title: Eur J Endocrinol
  doi: 10.1530/EJE-14-0304
– volume: 161
  start-page: 37
  issue: 1
  year: 2009
  ident: 1731_CR26
  publication-title: Eur J Endocrinol
  doi: 10.1530/EJE-09-0222
– volume: 51
  start-page: 616
  issue: 5
  year: 2002
  ident: 1731_CR18
  publication-title: Metabolism
  doi: 10.1053/meta.2002.32017
– volume: 1065
  start-page: 117
  year: 2013
  ident: 1731_CR30
  publication-title: Methods Mol Biol
  doi: 10.1007/978-1-62703-616-0_7
– volume: 10
  start-page: 115
  issue: 2
  year: 2007
  ident: 1731_CR28
  publication-title: Pituitary
  doi: 10.1007/s11102-007-0030-1
– volume: 38
  start-page: 147
  issue: 2
  year: 1987
  ident: 1731_CR21
  publication-title: Mathem Programm
  doi: 10.1007/BF02604639
– volume: 93
  start-page: 61
  issue: 1
  year: 2008
  ident: 1731_CR8
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2007-1191
– volume: 85
  start-page: 168
  issue: 1
  year: 2000
  ident: 1731_CR4
  publication-title: J Clin Endocrinol Metab
– volume: 6
  start-page: 175
  issue: 4
  year: 2003
  ident: 1731_CR13
  publication-title: Pituitary
  doi: 10.1023/B:PITU.0000023424.72021.e2
– year: 2010
  ident: 1731_CR16
  publication-title: J Clin Endocrinol Metabol Endocrine Soc
  doi: 10.1210/jc.2009-2670
– year: 2021
  ident: 1731_CR22
  publication-title: Mater Today Proc
  doi: 10.1016/j.matpr.2021.01.691
– volume: 52
  start-page: 181
  issue: 2
  year: 2003
  ident: 1731_CR15
  publication-title: Metabolism
  doi: 10.1053/meta.2003.50036
– volume: 25
  start-page: 102
  issue: 1
  year: 2004
  ident: 1731_CR9
  publication-title: Endocr Rev
  doi: 10.1210/er.2002-0022
– volume: 83
  start-page: 3808
  issue: 11
  year: 1998
  ident: 1731_CR12
  publication-title: J Clin Endocrinol Metab
– volume: 1
  start-page: 127
  issue: 1
  year: 1971
  ident: 1731_CR20
  publication-title: Mathem Programm.
  doi: 10.1007/BF01584082
– year: 2008
  ident: 1731_CR29
  publication-title: Eur J Endocrinol
  doi: 10.1530/EJE-08-0284
– year: 2003
  ident: 1731_CR17
  publication-title: J Endocrinol Invest
  doi: 10.1007/BF03345139
– volume: 63
  start-page: 618
  issue: 6
  year: 2019
  ident: 1731_CR31
  publication-title: Arch Endocrinol Metab
  doi: 10.20945/2359-3997000000192
– volume: 61
  start-page: 138
  issue: 1
  year: 2004
  ident: 1731_CR19
  publication-title: Clin Endocrinol (Oxf)
  doi: 10.1111/j.1365-2265.2004.02064.x
– volume: 57
  start-page: 555
  issue: 4
  year: 2011
  ident: 1731_CR32
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2010.150631
– volume: 20
  start-page: 46
  issue: 1
  year: 2017
  ident: 1731_CR6
  publication-title: Pituitary
  doi: 10.1007/s11102-017-0797-7
– volume: 70
  start-page: 1106
  issue: 5
  year: 2012
  ident: 1731_CR14
  publication-title: Neurosurgery
  doi: 10.1227/NEU.0b013e31823f5c16
– volume: 7
  start-page: 443
  issue: 5
  year: 2013
  ident: 1731_CR10
  publication-title: Expert Opin Med Diagn
  doi: 10.1517/17530059.2013.820181
– volume: 21
  start-page: 597
  issue: 3
  year: 1992
  ident: 1731_CR5
  publication-title: Endocrinol Metab Clin North Am
  doi: 10.1016/S0889-8529(18)30204-4
– volume: 26
  start-page: 11
  issue: 1
  year: 2015
  ident: 1731_CR24
  publication-title: Trends Endocrinol Metab
  doi: 10.1016/j.tem.2014.10.005
– volume: 14
  start-page: 3484
  issue: 22
  year: 2008
  ident: 1731_CR7
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.14.3484
– volume: 97
  start-page: 3983
  issue: 11
  year: 2012
  ident: 1731_CR27
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2012-2477
– volume: 165
  start-page: 873
  issue: 6
  year: 2011
  ident: 1731_CR23
  publication-title: Eur J Endocrinol
  doi: 10.1530/EJE-11-0657
– volume: 99
  start-page: 3933
  issue: 11
  year: 2014
  ident: 1731_CR1
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2014-2700
– volume: 42
  start-page: 397
  issue: 4
  year: 2019
  ident: 1731_CR3
  publication-title: J Endocrinol Invest
  doi: 10.1007/s40618-018-0928-7
SSID ssj0037387
Score 2.3299513
Snippet Background In patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose...
In patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose tolerance...
BackgroundIn patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 981
SubjectTerms Accuracy
Acromegaly
Acromegaly - diagnosis
Blood Specimen Collection
Cohort Studies
Endocrinology
Glucose tolerance
Glucose Tolerance Test
Human Growth Hormone
Humans
Insulin-Like Growth Factor I
Internal Medicine
Medicine
Medicine & Public Health
Metabolic Diseases
Original Article
Title Optimal timing of blood samplings to detect GH inhibition during oral glucose tolerance test
URI https://link.springer.com/article/10.1007/s40618-021-01731-0
https://www.ncbi.nlm.nih.gov/pubmed/35098493
https://www.proquest.com/docview/2649015547
https://www.proquest.com/docview/2624200399
Volume 45
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVLSH
  databaseName: SpringerLink Journals
  customDbUrl:
  mediaType: online
  eissn: 1720-8386
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0037387
  issn: 1720-8386
  databaseCode: AFBBN
  dateStart: 19970101
  isFulltext: true
  providerName: Library Specific Holdings
– providerCode: PRVAVX
  databaseName: SpringerLINK - Czech Republic Consortium
  customDbUrl:
  eissn: 1720-8386
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0037387
  issn: 1720-8386
  databaseCode: AGYKE
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: http://link.springer.com
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dS-QwEB90hcMXv_V6ehLBN63stmnSPqq4LoreiwseCCVfu4peV267L_fX30ybVk5PwZdS6KRNM5PML8xvJgD7GbpYEXEVKqW7IRcjHaZWqjBSKomEogp8lOB8dS0GQ35xm9z6pLBpw3ZvQpLVSt0mu5HrSUOiFKAVxXidh4Wq3lYHFo7Pf16eNSswFeuRPkHm_y3_dUJvkOWbqGjlbPrLMGy6WXNMHo9mpT4yf15VcPzsf6zAkkef7Lg2l1WYc8UafLny8fV1uPuBK8gvlCjpsK8xm4xYxWxnU0XM82I8ZeWEWUeRB3Y-YA_F_YOuSF-szndklPDPPA8eZZ8cHdyBd_jjGzDsn92cDkJ__kJoYpmUoRUa949WqdQIraWW1jkjHUIeVGDPpLgZMdzFPZFpK8nZInwUsbCpdCk2yuJN6BSTwn0FFnFLlcG63ZFJuY0iHWc84RE6Cp6YnhgF0GsUkhtfnJzOyHjK27LK1bDlOGx5NWx5N4CDts1zXZrjQ-mdRs-5n6bTHNEg4aGEywD22sc4wShqogo3mZEMohhKYc4C2Krto_1cjHAr5VkcwGGj65eXv9-Xb58T34bFiJIuKprlDnTK3zP3HaFQqXfR8vsnJ9e7fgb8Ba-O_3o
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED9BJ8Fe-BhsBAbzJN4gU-s4dvI4TVvL2o6XVhoSUuSvjomRIpq-8NdzlziZtgHSXqJIOSeOz_b9rLvfHcD7HE2s5ELHWpt-LOTCxJlTOuZap1xqysBHBOfpmRzNxel5eh5IYas22r11SdY7dUd2I9OTxRRSgLMowetD2BB4QOE92DgcfhkftzswJetRgSDz95Y3jdAdZHnHK1obm5OnMG-72cSYfD9YV-bA_r6VwfG-__EMngT0yQ6b6fIcHvhyCx5Ng3_9BXz9jDvID5SoqNjXBVsuWB3ZzlaaIs_LixWrlsx58jyw4Yhdlt8uTR30xRq-IyPCPwtx8Ch75alwB97hj7-E-cnx7GgUh_oLsU1UWsVOGjw_Oq0zK41RRjnvrfIIeVCBA5vhYcQKnwxkbpwiY4vwUSbSZcpn2ChPtqFXLkv_ChgXjjKD9fsLmwnHuUlykQqOhkKkdiAXEQxahRQ2JCenGhlXRZdWuR62AoetqIet6EfwoWvzs0nN8V_p3VbPRVimqwLRIOGhVKgI9rvHuMDIa6JLv1yTDKIYojDnEew086P7XIJwKxN5EsHHVtfXL_93X17fT3wPHo9m00kx-XQ2fgObnAgYdcjlLvSqX2v_FmFRZd6FVfAHoZUA7A
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ZT9wwEB5RkFBfuEohXDVS30pgN3Hs5BEBy7acD0WiUqXIVwABWcRmX_j1zOTibKWqL1GkjBNnxvZ81sx8BviaoIsVAVe-Urrjc5FpP7ZS-YFSUSAUMfBRgfPRseif8R_n0fmzKv4y270JSVY1DcTSlBdbdzbbagvfyA3FPqUX4IgK8foBJnBrInGkT2zv_zrYa1ZjIu6RdbHM-y1fOqQ3KPNNhLR0PL1pUE2Xq3yT681RoTfNwys2x__5pxmYqlEp266G0SyMuXwOJo_quPsn-H2CK8stShR0CNgFG2SszHhnQ0UZ6fnFkBUDZh1FJNh-n13ll1e6TAZjVR0kIyIAVufHo-yNowM98A6VMA9nvb2fO32_PpfBN6GMCt8KjftKq1RshNZSS-uckQ6hEBq2a2LcpBjuwq5ItJXkhBFWilDYWLoYGyXhZxjPB7lbBBZwS4xhnU5mYm6DQIcJj3iADoRHpisyD7qNcVJTk5bT2Rk3aUu3XKotRbWlpdrSjgff2jZ3FWXHX6VXGpun9fQdpogSCSdFXHqw3j7GiUfRFJW7wYhkEN1QaXPiwUI1VtrPhQjDYp6EHmw0dn96-Z_7svRv4l9g8nS3lx5-Pz5Yho8B1WVQqk20AuPF_citIloq9Fo9IR4BeIAJ0Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Optimal+timing+of+blood+samplings+to+detect+GH+inhibition+during+oral+glucose+tolerance+test&rft.jtitle=Journal+of+endocrinological+investigation&rft.au=Bioletto%2C+F&rft.au=Prencipe%2C+N&rft.au=Berton%2C+A+M&rft.au=Bona%2C+C&rft.date=2022-05-01&rft.pub=Springer+Nature+B.V&rft.issn=0391-4097&rft.eissn=1720-8386&rft.volume=45&rft.issue=5&rft.spage=981&rft.epage=987&rft_id=info:doi/10.1007%2Fs40618-021-01731-0&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1720-8386&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1720-8386&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1720-8386&client=summon